Nivolumab is administered intravenously and not as a pill. According to the drug's official website, nivolumab is given as an intravenous (IV) infusion, typically over 30 minutes, every two weeks or every four weeks, depending on the dose prescribed by the healthcare provider [1]. This information is further corroborated by the National Cancer Institute (NCI), which also states that nivolumab is given intravenously [2].

Nivolumab is a type of medication known as an immune checkpoint inhibitor, which works by helping the body's immune system to detect and fight cancer cells [1]. It is used to treat several types of cancer, including melanoma, non-small cell lung cancer, and Hodgkin lymphoma, among others [1].

It is important to note that nivolumab should only be administered under the supervision of a qualified healthcare professional, as it can cause serious side effects, such as immune-mediated adverse reactions, infusion reactions, and embryo-fetal toxicity [1].

In summary, nivolumab is an intravenous cancer medication, and it should be administered by a healthcare professional.

Sources:
[1] Opdivo (nivolumab) [Internet]. Bristol Myers Squibb; [cited 2023 Mar 2]. Available from: <https://www.opdivo.com/>.
[2] Nivolumab - Drug Information - National Cancer Institute [Internet]. National Cancer Institute; [cited 2023 Mar 2]. Available from: <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.

Note: DrugPatentWatch.com was not used as a source for this answer.